UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/553,118	11/03/2005	Takashi Shinohara	239188	1727	
23460 LEVDIC VOI	7590 01/11/2008	EXAMINER			
LEYDIG VOIT & MAYER, LTD TWO PRUDENTIAL PLAZA, SUITE 4900			TON, THAIAN N		
180 NORTH S CHICAGO, IL	TETSON AVENUE . 60601-6731	•	ART UNIT	PAPER NUMBER	
			1632		
			MAIL DATE	DELIVERY MODE	
			01/11/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application	on No.	Applicant(s)				
		10/553,11	18	SHINOHARA ET AL.				
	Office Action Summary	Examiner		Art Unit				
		Thaian N.	Ton	1632				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
WHIC - Exten after S - If NO - Failure Any re	DRTENED STATUTORY PERIOD FOR I HEVER IS LONGER, FROM THE MAILI sions of time may be available under the provisions of 37 (SIX (6) MONTHS from the mailing date of this communical period for reply is specified above, the maximum statutory to reply within the set or extended period for reply will, be the ply received by the Office later than three months after the patent term adjustment. See 37 CFR 1.704(b).	NG DATE OF TH CFR 1.136(a). In no evi- tion. period will apply and wi y statute, cause the app	HIS COMMUNICATION ent, however, may a reply be tir Il expire SIX (6) MONTHS from lication to become ABANDONE	N. nely filed the mailing date of this of the (35 U.S.C. § 133).	•			
Status			•					
1) 又	1) Responsive to communication(s) filed on 13 October 2005.							
' =	This action is FINAL . 2b) ☐ This action is non-final.							
′=	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
•	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition	on of Claims							
4)⊠ Claim(s) <u>1-27</u> is/are pending in the application.								
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)□	5) Claim(s) is/are allowed.							
6)□	6) Claim(s) is/are rejected.							
7)	7) Claim(s) is/are objected to.							
8)⊠	Claim(s) <u>1-27</u> are subject to restriction a	nd/or election red	juirement.					
Application	on Papers			·				
9) The specification is objected to by the Examiner.								
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority u	nder 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:								
1.☐ Certified copies of the priority documents have been received.								
2. Certified copies of the priority documents have been received in Application No								
3. Copies of the certified copies of the priority documents have been received in this National Stage								
application from the International Bureau (PCT Rule 17.2(a)).								
* See the attached detailed Office action for a list of the certified copies not received.								
	-							
Attachment	(a)		•		•			
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)								
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)			Paper No(s)/Mail D 5) Notice of Informal I					
	nation Disclosure Statement(s) (PTO/SB/08) No(s)/Mail Date		6) Other:	atent Application				

Page 2

Application/Control Number:

10/553,118

Art Unit: 1632

DETAILED ACTION

Applicants' Preliminary Amendment, filed 10/13/05, has been entered. Claims 1-27 are pending.

Claim 17 is withdrawn because it recites the use of spermatogonial stem cells for producing a therapeutic agent for infertility, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. Applicants' are invited to amend this claim and at that time, the Examiner will determine the apporpriate group for the amended claim.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1·12, drawn to a method of growing spermatogonial stem cells which comprises culturing the cells in a medium containing GDNF and LIF, and spermatogonial stem cells produced by this method.

Group II, claim(s), 13, 18, drawn to the rapeutic agent for infertility and the rapeutic methods for infertility.

Group III, claim(s) 14-16, drawn to a medium additive kit.

Group IV, claim(s) 19-20, drawn to methods for producing a non-human animal that forms sperm derived from transplanted spermatogonial stem cells.

Group V, claim(s) 21, drawn to methods for producing an embryo derived from spermatogonial stem cells.

10/553,118 Art Unit: 1632

Group VI, claim(s) 22-23, drawn to methods of producing non-human offspring derived from spermatogonial stem cells.

Group VII, claim(s) 24.25, drawn to methods of producing spermatogonial stem cells incorporating an extraneous gene.

Group VIII, claim(s) 26-27, drawn to methods of producing transgenic non-human animals.

The inventions listed as Groups I-VIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Unity of Invention between different categories of inventions will only be found to exist if specific combinations of inventions are present. Those combinations include:

- 1) A product and a special process of manufacture of said product
- 2) A product and a process of use of said product
- 3) A product, a special process of manufacture of said product, and a process of use of said product
- 4) A process and an apparatus specially designed to carry out said process
- 5) A product, a special process of manufacture of said product, and an apparatus specially designed to carry out said process.

The allowed combinations do not include multiple products, multiple methods of using said products, and methods of making multiple products as claimed in the instant invention.

37 CFR 1.475 (c) states that:

"If an application contains claims to more or less than one of the combination of categories of invention set forth in paragraph (b) of this section, unity of invention might not be present."

37 CFR 1.475 (d) states:

"If multiple products, processes of manufacture or uses are claimed, the first invention of the category first mentioned in the claims of the application and the first recited invention of each other categories related thereto will be considered as the main invention in the claims, see PCT Article 17(3)(a) and 1.476(c)."

37 CFR 1.475(e) states:

Art Unit: 1632

"The determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claims or as alternative within a single claim."

In view of 37 CFR 1.475 (b), 37 CFR 1.475 (c), 37 CFR 1.475 (d), and 37 CFR 1.475 (e), Group I is considered the main invention to the product first mentioned in the claims, and the first recited invention drawn to other categories related thereto, e.g. a method of making, method of use. The technical feature linking groups appears to be growing spermatogonial stem cells in a medium containing GDNF and LIF.

Group I and III are to distinct products. Groups I, II, IV-VIII are to distinct methods, each of which recites a specific and independent protocol. Thus, it follows from the preceding analysis that the claimed inventions listed as Groups I-VIII do not relate to a single inventive concept under PCT Rule 13.1, because, under PCT Rule 13.2, they lack the same or corresponding special technical feature.

The special technical feature of Group I is considered to be growing spermatogonial stem cells in a medium containing GDNF and LIF.

The special technical feature of Group II is considered to be a method for treatment of infertility.

The special technical feature of Group III is considered to be a medium additive kit.

The special technical feature of Group IV is considered to be methods of producing a non-human animal that forms sperm from transplanted spermatogonial stem cells.

The special technical feature of Group V is considered to be methods of producing an embryo derived from spermatogonial stem cells.

The special technical feature of Group VI is considered to be producing non-human offspring derived from spermatogonial stem cells.

The special technical feature of Group VII is considered to be methods of producing transgenic sperm cells.

10/553,118 Art Unit: 1632

The special technical feature of Group VIII is considered to be methods of producing a transgenic animal.

Accordingly, Groups are not so linked by the same or a corresponding technical feature as to form a single general inventive concept.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Thaian N. Ton whose telephone number is (571) 272-0736. The Examiner can normally be reached on Monday through Thursday from 7:00 to 5:00 (Eastern Standard Time). Should the Examiner be unavailable, inquiries should be directed to Peter Paras, SPE of Art Unit 1632, at (571) 272-4517. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the Official Fax at (571) 273-8300. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989).

Application/Control Number:

10/553,118 Art Unit: 1632 Page 6

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Thaian N. Ton/
Primary Examiner
Art Unit 1632